Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)

Inclusion Criteria: * Male and female patients ≥18 years of age at the time of consent. * A body mass index (BMI) within the range of 15 - 38 kg/m2. BMI = Body weight (kg) / \[Height (m)\]2. * Confirmation of IgA Nephropathy verified by biopsy performed within the previous three years. * All patients must be vaccinated prior to dosing with MenACWY Menactra® polysaccharide diphtheria toxoid conjugate vaccination against Neisseria meningitidis serogroups A, C, Y, and W-135. MenB meningococcal serogroup B vaccine (Bexsero®) will be administered per local guidelines. * Hemoglobin ≥ 10g/dL and platelet count ≥ 100,000/mm3 * Female and male participates must agree to use contraceptives Exclusion Criteria: * Evidence of severe urinary obstruction or difficulty in voiding; any urinary tract disorder other than IgAN at screening and before dosing with NM8074. * Require dialysis or plasma exchange within 12 weeks prior to screening. * Presence of crescent formation in ≥50% of glomeruli assessed on renal biopsy. * History of bone marrow, hematopoietic stem cells, or solid organ transplantation. * Use of other investigational drugs at the time of enrolment, or within 5 half-lives of enrolment or within 3 months to study day 1 whichever is longer. * Severe concurrent co-morbidities not amenable to active treatment, e.g., patients with severe kidney disease (CKD stage 4, chronic dialysis). * Clinically significant abnormal ECG during screening. * Currently active systemic infection or s…